Partner Headlines - FOLD

  1. Earnings Scheduled For March 3, 2014

    Benzinga
  2. UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious ...

    Benzinga
  3. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  4. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  5. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  6. Amicus, Biogen Announce Deal for Discovery, Development, Commercialization ...

    Benzinga
  7. Amicus Therapeutics Says Added 6-Month Results from Phase 3 Fabry ...

    Benzinga
  8. Amicus Therapeutics Advances Chaperone-ERT Combo Platform in ...

    Benzinga
  9. Amicus Announces Positive Phase 2 Results for Chaperone-Enzyme ...

    Benzinga
  10. Stocks Hitting 52-Week Lows

    Benzinga
  11. UPDATE: Wedbush Downgrades Amicus Therapeutics to Underperform ...

    Benzinga
  12. Option Traders Call a Bottom for Amicus Therapeutics

    SchaeffersResearch
  13. GlaxoSmithKline

    IBD
  14. Amicus, Glaxo Release Top-Line Six-Month Primary Treatment Period ...

    Benzinga
  15. Amicus Therapeutics Announces Additional Preliminary Results ...

    Benzinga
  16. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  17. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  18. UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus ...

    Benzinga
  19. Amylin Pharmaceuticals, Best Buy Among Stocks Up on High Volume ...

    FoxBusiness
  20. Benzinga's Top Upgrades with Color for May 8, 2012

    Benzinga
  21. UPDATE: J.P. Morgan Upgrades Amicus Therapeutics

    Benzinga
  22. From Earlier: Amicus Therapeutics Prices Underwritten Offering ...

    Benzinga
  23. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-K)

    GuruFocus
  24. Amicus Therapeutics Presents Preclinical Studies of Chaperone ...

    Benzinga
  25. Amicus Therapeutics Announces Positive Preliminary Results From ...

    Benzinga
Trading Center